CGTX vs. JATT, DTIL, TIL, ATRA, ELUT, ATHA, PLX, TSBX, SCYX, and IKNA
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include JATT Acquisition (JATT), Precision BioSciences (DTIL), Instil Bio (TIL), Atara Biotherapeutics (ATRA), Elutia (ELUT), Athira Pharma (ATHA), Protalix BioTherapeutics (PLX), Turnstone Biologics (TSBX), SCYNEXIS (SCYX), and Ikena Oncology (IKNA). These companies are all part of the "medical" sector.
Cognition Therapeutics (NASDAQ:CGTX) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
Cognition Therapeutics presently has a consensus price target of $6.67, indicating a potential upside of 243.64%. Given Cognition Therapeutics' higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than JATT Acquisition.
Cognition Therapeutics received 8 more outperform votes than JATT Acquisition when rated by MarketBeat users.
43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 23.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cognition Therapeutics had 7 more articles in the media than JATT Acquisition. MarketBeat recorded 7 mentions for Cognition Therapeutics and 0 mentions for JATT Acquisition. Cognition Therapeutics' average media sentiment score of 0.25 beat JATT Acquisition's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.
JATT Acquisition's return on equity of -49.58% beat Cognition Therapeutics' return on equity.
Summary
Cognition Therapeutics beats JATT Acquisition on 6 of the 10 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
